US20060104912A1 - Mousse composition - Google Patents
Mousse composition Download PDFInfo
- Publication number
- US20060104912A1 US20060104912A1 US11/303,298 US30329805A US2006104912A1 US 20060104912 A1 US20060104912 A1 US 20060104912A1 US 30329805 A US30329805 A US 30329805A US 2006104912 A1 US2006104912 A1 US 2006104912A1
- Authority
- US
- United States
- Prior art keywords
- weight
- composition
- agent
- active agent
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Definitions
- the present invention provides a composition for the topical administration of pharmaceutical active ingredients.
- the foam composition is an aqueous emulsion system.
- the foam composition upon actuation produces a stabilised, homogeneous, expandable foam which breaks easily with shear.
- a composition of this type is often referred to as an aerosol foam or “mousse”.
- topical lotions and creams known or suggested in the prior art for delivering pharmaceutically active ingredients contain large amounts of petrolatum or some other occlusive agent to act as a barrier over the skin. This barrier reduces the evaporation of moisture from the skin which leads to increased moisture in the stratum comeum and in the epidermis and enhances the topical delivery of the pharmaceutical active ingredients.
- a mousse composition could be provided that enhanced the topical delivery of the pharmaceutical active ingredient while preferably still providing a pharmaceutically elegant and consumer acceptable composition.
- the pharmaceutically active ingredient being insoluble in both water and the occlusive agent
- the present invention is predicated on the surprising discovery that a mousse formulation with a relatively low amount of an occlusive agent is still able to reduce trans epidermal water loss and hence in theory increase skin permeability to effect greater drug skin penetration while remaining an elegant and consumer acceptable composition.
- the water-insoluble pharmaceutically active ingredient may be any suitable type.
- An analgesic such as capsaicin or piroxicam, antifungal such as clotrimazole or miconazole nitrate, antibacterial such as nitrofurazone or gramcidin, anaesthetic such as benzocaine or lidocaine, antiviral such as aciclovir or penciclovir, antipruritic such as crotamiton or phenol, antihistamine such as chlorpheniramine or triprolidine, xanthine such as caffeine, sex hormone such as oestradiol or testosterone, anti-inflammatory agent or corticosteroid may be used.
- a corticosteroid is preferred.
- the corticosteroids may be selected from one or more of the group consisting of, betamethasone valerate and clobetasol propionate.
- Clobetasol propionate is preferred.
- the pharmaceutically active ingredient may be present in any effective amounts.
- the pharmaceutically active ingredient may be present in amounts of approximately 0.005% by weight to approximately 10% by weight, preferably approximately 0.05% to approximately 1% by weight, based on the total weight of the pharmaceutical aerosol foam composition.
- the aerosol foam base can be made using compositions that are well known in the art.
- the pharmaceutical aerosol foam composition may further include an effective amount of an aerosol propellant.
- the aerosol propellant used in the mousse composition may be any suitable gas, such as a hydrocarbon, e.g. propane, butane, CFCs, HFCs, nitrogen or air.
- the aerosol propellant is a hydrocarbon.
- the aerosol propellant is a hydrocarbon it may be present in an amount of from approximately 2.5% to 20% by weight, preferably 2.5% to 7.5% by weight, based on the total weight of the pharmaceutical mousse composition.
- the propellant may be introduced into the mousse composition at the time of filling utilising for example a standard aerosol dispenser, e.g. a spray can arrangement.
- the occlusive agent utilised in the pharmaceutical composition according to the present invention may be any excipient or combination thereof that provides an occlusive layer or hydration barrier to the skin.
- An occlusive layer or hydration barrier is a layer or barrier sufficient to result in reduction in trans epidermal water loss, which results in skin hydration.
- Suitable occlusive agents may be selected from one or more of the group consisting of mineral oils and greases, long chain acids, animal fats and greases, vegetable fats and greases, water insoluble polymers and the like.
- the occlusive agent is petrolatum.
- the occlusive agent is present in an amount sufficient to permit the formation of an occlusive layer or hydration barrier on the skin of the patient. Surprisingly applicants have discovered it is possible to form such an occlusive layer with a relatively low amount of occlusive agent.
- the amount of occlusive agent in the mousse composition may be up to approximately 55%, preferably approximately 40% or less by weight based on the total weight of the composition. In a preferred embodiment of the invention the amount of occlusive agent in the mousse composition may be up to approximately 50%, more preferably from approximately 20 to 50% by weight.
- the pharmaceutical mousse composition may further include an effective amount of an emulsifier and/or surfactant.
- the emulsifier or surfactant may be selected from one or more of the group consisting of non-ionic, anionic and cationic surfactants, e.g. fatty alcohols, fatty acids and fatty acid salts thereof.
- Suitable emulsifiers or surfactants include pharmaceutically acceptable, non-toxic, non-ionic, anionic and cationic surfactants.
- suitable non-ionic surfactants include glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as polyethylene glycol (400) monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene (40) stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene (20) stearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate, sorbitan esters such as sorbitan monostearate, alkyl glycosides such as cetearyl glucoside, fatty acid ethanolamides and their derivatives such as the diethanolamide of stearic acid, and the like.
- Suitable anionic surfactants are soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate.
- alkali soaps such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate.
- Organic amine soaps also included, include organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate.
- Another class of suitable soaps is the metallic soaps, salts of polyvalent metals and aliphatic carboxylic acids, usually fatty acids, such as aluminium stearate.
- Suitable anionic surfactants include sulfated fatty acid alcohols such as sodium lauryl sulfate, sulfated oils such as the sulfuric ester of ricinoleic acid disodium salt, and sulfonated compounds such as alkyl sulfonates including sodium cetane sulfonate, amide sulfonates such as sodium N-methyl-N-oleyl laurate, sulfonated dibasic acid esters such as sodium dioctyl sulfosuccinate, alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate, alkyl naphthalene sulfonates such a sodium isopropyl naphthalene sulfonate, petroleum sulfonate such as aryl napthalene with alkyl substitutes.
- suitable cationic surfactants include amine salts such as octade
- Surfactants which are a mixture of sorbitan monostearate and polysorbate 60 are preferred.
- the emulsifier component may be present in any suitable stabilising amount.
- the emulsifier component may be in an amount where the ratio of emulsifier component to the occlusive agent, active pharmaceutical ingredient and cosolvent is about 1:5.
- the emulsifier component may be present in an amount of from approximately 1% to 15% by weight, preferably approximately 2.0% to 5.0% by weight, based on the total weight of the pharmaceutical mousse composition.
- the aqueous solvent may be present in an amount of from approximately 25% to 95% by weight, preferably approximately 70% to 85% by weight, based on the total weight of the pharmaceutical mousse composition.
- the composition further includes an organic cosolvent.
- the organic solvent may be an ester of a fatty acid for example a C12-C15 alkyl benzoate, a medium to long chain alcohol, an aromatic and/or alkyl pyrollidinone, an aromatic and/or alkyl, and/or cyclic ketone, an aromatic and/or alkyl, and/or cyclic ether, substituted and/or unsubstituted single or multiple ring aromatic, straight chain and/or branched chain and/or cyclic alkane or silicone.
- the organic cosolvent may be present in amounts of approximately 0.25% to 50% by weight, preferably 0.5 to 2% by weight, based on the total weight of the pharmaceutical mousse composition.
- Preferred organic cosolvents include C12-C15 alkyl benzoates (FINSOLV TN) and caprylic/capric triglyceride (CRODAMOL GTCC).
- the pharmaceutical mousse composition according to the present invention may also contain other non-essential ingredients.
- the composition may contain up to 10 weight percent of conventional pharmaceutical adjuvants.
- adjuvants or additives include preservatives, stabilisers, antioxidants, pH adjusting agents, skin penetration enhancers, and viscosity modifying agents.
- FIG. 1 illustrates the effect of petrolatum content on in vitro epidermal penetration of clobetasol from topical mousse formulations 72 hours after application of 10 mg/cm 2 of formulation.
- FIG. 2 illustrates the effect of petrolatum content on the rate of transepidermal water loss (TEWL) determined on the forearm of a healthy volunteer 30 and 120 minutes after topical application of 10 mg/cm 2 of formulation.
- TEWL transepidermal water loss
- FIG. 3 illustrates relative decreases in the rate of transepidermal water loss (TEWL) observed on the forearm of a healthy volunteer with increasing concentrations of petrolatum in topically applied formulations.
- TEWL transepidermal water loss
- Epidermal membranes Donated human female abdominal skin was separated by blunt dissection, to remove subcutaneous fat and extraneous tissue, and immersed in water at 60° C. for 2 minutes to allow separation of the epidermal-dermal junction. Epidermal membranes were lifted from the dermis by gently rolling from one end with the fingers and stored on filter paper, stratum comeum uppermost, at ⁇ 20° C. until use.
- Epidermal membranes were mounted, stratum comeum uppermost and facing the donor chamber, on filter paper between the two halves of standard horizontal glass Franz-type diffusion cells (area approx. 1.3 cm 2 ).
- the bottom half of the diffusion cells was filled with approximately 3.5 ml of receptor medium (either 20% ethanol in distilled water for intact epidermal membrane studies or Baxter 20% Intralipid® solution for stripped skin studies) and continuously stirred with small magnetic fleas. Assembled cells were semi-submerged in a water bath maintained at 35 ⁇ 0.1° C.
- Mousse formulations containing 0.05% clobetasol with the inclusion of 0, 30 or 50% petrolatum were gently applied to the donor chamber with a round-ended plastic rod which was wiped around the skin surface such that the skin was covered by a total dose of approximately 10 mg/cm 2 .
- the weight of formulation applied was verified from the difference in weight of the application rod and small weigh boat from which the formulation had been applied before and after dosing.
- Clobetasol was allowed to penetrate into the epidermis for 72 hrs. after which time the remaining formulation was removed from the skin surface by washing and a single tape strip was performed to ensure that minimal. ‘unpenetrated’ material remained on the surface of the epidermis. All washes and tape strips were retained for quantification of clobetasol concentration. The area of epidermis exposed to the formulation was then removed from the membrane using a stainless steel punch which was cleaned with methanol between samples to avoid any cross contamination of clobetasol. Epidermal, tape and wash samples were all assayed for clobetasol concentration by high performance liquid chromatography.
- FIG. 1 shows the fraction of the applied amount of clobetasol that was found to have penetrated into the epidermal membranes during the study. It can be clearly seen that inclusion of petrolatum in the mousse formulations has increased the amount of clobetasol penetrating into the epidermis of both intact and stripped skin samples. The recovery of the applied amounts of clobetasol in the washes, tape strip and epidermis was greater than 75% in all cases.
- the aim of the study was to determine whether increasing the concentration of petrolatum in topical mousse formulations could effectively occlude the underlying skin and thereby lead to increased local hydration which in turn is known to improve the percutaneous penetration of suitable drugs.
- TEWL transepidermal water loss
- each mousse was weighed out onto a 2 cm wide glass slide which was then used to wipe the mousse evenly across each one of the marked test squares before being reweighed to determine the total amount of mousse transferred onto the skin.
- FIG. 2 shows the actual rate of TEWL (g/hr/m 2 ) determined at each of the test sites prior to treatment and again at 30 and 120 minutes after mousse application. A decrease in the rate of TEWL was observed with Increasing concentrations of petrolatum in the mousse formulations at both 30 and 120 minutes following application. FIG. 2 clearly shows the relationship between the % of petrolatum content in each of the test mousses and the resultant relative change in the rate of TEWL determined at 30 and 120 minutes after formulation application.
- the aim of the second part of this study was to assess the degree of occlusivity afforded by the 50% petrolatum mousse formulation in a number of healthy volunteers.
Abstract
A pharmaceutical aerosol foam composition including an effective amount of a pharmaceutically active ingredient; an occlusive agent; an aqueous solvent; and an organic cosolvent, the pharmaceutically active ingredient being insoluble in both water and the occlusive agent; the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.
Description
- The present invention provides a composition for the topical administration of pharmaceutical active ingredients.
- Various aerosol and non-aerosol quick breaking and slow breaking foams for the topical delivery of pharmaceutical active ingredients are known in the prior art. In particular, the foam composition is an aqueous emulsion system. The foam composition upon actuation produces a stabilised, homogeneous, expandable foam which breaks easily with shear. A composition of this type is often referred to as an aerosol foam or “mousse”.
- It is known to use mousse compositions to topically deliver pharmaceutical active ingredients. An example of such a composition is in Australian patent application 80257/87 which discloses a mousse composition for the topical delivery of the pharmaceutically active ingredient minoxidil. However the efficiency of such systems to deliver pharmaceutically active ingredients is limited.
- Moreover, the majority of topical lotions and creams known or suggested in the prior art for delivering pharmaceutically active ingredients contain large amounts of petrolatum or some other occlusive agent to act as a barrier over the skin. This barrier reduces the evaporation of moisture from the skin which leads to increased moisture in the stratum comeum and in the epidermis and enhances the topical delivery of the pharmaceutical active ingredients.
- However, in practice it would not be desirable to include such large amounts of an occlusive agent in a mousse formulation because when dispensed the mousse formulation would be a less stable foam, and upon application, the occlusive agent would leave a greasy, sticky lather on the skin which would not be considered acceptable to the consumer.
- In prior art U.S. Pat. Nos. 5,002,680 and 4,981,677, there is disclosed mousse compositions that contain an occlusive agent such as petrolatum. These compositions are directed towards cosmetic purposes, and provide no disclosure on their suitability or otherwise to enhance the topical delivery of pharmaceutical active ingredients. Furthers in respect of U.S. Pat. No. 4,981,677 the formulation includes a starch component. It is accordingly not apparent that an occlusive layer would be formed.
- Accordingly, it would be a significant advance in the art if a mousse composition could be provided that enhanced the topical delivery of the pharmaceutical active ingredient while preferably still providing a pharmaceutically elegant and consumer acceptable composition.
- In a first aspect of the present invention there is provided a pharmaceutical aerosol foam composition including an effective amount of
- a pharmaceutically active ingredient
- an occlusive agent
- an aqueous solvent; and
- an organic cosolvent;
- the pharmaceutically active ingredient being insoluble in both water and the occlusive agent;
- the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.
- The present invention is predicated on the surprising discovery that a mousse formulation with a relatively low amount of an occlusive agent is still able to reduce trans epidermal water loss and hence in theory increase skin permeability to effect greater drug skin penetration while remaining an elegant and consumer acceptable composition.
- The water-insoluble pharmaceutically active ingredient may be any suitable type. An analgesic such as capsaicin or piroxicam, antifungal such as clotrimazole or miconazole nitrate, antibacterial such as nitrofurazone or gramcidin, anaesthetic such as benzocaine or lidocaine, antiviral such as aciclovir or penciclovir, antipruritic such as crotamiton or phenol, antihistamine such as chlorpheniramine or triprolidine, xanthine such as caffeine, sex hormone such as oestradiol or testosterone, anti-inflammatory agent or corticosteroid may be used. A corticosteroid is preferred. The corticosteroids may be selected from one or more of the group consisting of, betamethasone valerate and clobetasol propionate.
- Clobetasol propionate is preferred.
- The pharmaceutically active ingredient may be present in any effective amounts. The pharmaceutically active ingredient may be present in amounts of approximately 0.005% by weight to approximately 10% by weight, preferably approximately 0.05% to approximately 1% by weight, based on the total weight of the pharmaceutical aerosol foam composition.
- The aerosol foam base can be made using compositions that are well known in the art.
- The pharmaceutical aerosol foam composition may further include an effective amount of an aerosol propellant. The aerosol propellant used in the mousse composition may be any suitable gas, such as a hydrocarbon, e.g. propane, butane, CFCs, HFCs, nitrogen or air. In a preferred embodiment the aerosol propellant is a hydrocarbon. Where the aerosol propellant is a hydrocarbon it may be present in an amount of from approximately 2.5% to 20% by weight, preferably 2.5% to 7.5% by weight, based on the total weight of the pharmaceutical mousse composition. The propellant may be introduced into the mousse composition at the time of filling utilising for example a standard aerosol dispenser, e.g. a spray can arrangement.
- The occlusive agent utilised in the pharmaceutical composition according to the present invention may be any excipient or combination thereof that provides an occlusive layer or hydration barrier to the skin. An occlusive layer or hydration barrier is a layer or barrier sufficient to result in reduction in trans epidermal water loss, which results in skin hydration. Suitable occlusive agents may be selected from one or more of the group consisting of mineral oils and greases, long chain acids, animal fats and greases, vegetable fats and greases, water insoluble polymers and the like. In a preferred embodiment the occlusive agent is petrolatum.
- The occlusive agent is present in an amount sufficient to permit the formation of an occlusive layer or hydration barrier on the skin of the patient. Surprisingly applicants have discovered it is possible to form such an occlusive layer with a relatively low amount of occlusive agent. For example the amount of occlusive agent in the mousse composition may be up to approximately 55%, preferably approximately 40% or less by weight based on the total weight of the composition. In a preferred embodiment of the invention the amount of occlusive agent in the mousse composition may be up to approximately 50%, more preferably from approximately 20 to 50% by weight.
- The pharmaceutical mousse composition may further include an effective amount of an emulsifier and/or surfactant.
- The emulsifier or surfactant may be selected from one or more of the group consisting of non-ionic, anionic and cationic surfactants, e.g. fatty alcohols, fatty acids and fatty acid salts thereof.
- Suitable emulsifiers or surfactants include pharmaceutically acceptable, non-toxic, non-ionic, anionic and cationic surfactants. Examples of suitable non-ionic surfactants include glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as polyethylene glycol (400) monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene (40) stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene (20) stearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate, sorbitan esters such as sorbitan monostearate, alkyl glycosides such as cetearyl glucoside, fatty acid ethanolamides and their derivatives such as the diethanolamide of stearic acid, and the like. Examples of suitable anionic surfactants are soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate. Organic amine soaps, also included, include organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate. Another class of suitable soaps is the metallic soaps, salts of polyvalent metals and aliphatic carboxylic acids, usually fatty acids, such as aluminium stearate. Other classes of suitable anionic surfactants include sulfated fatty acid alcohols such as sodium lauryl sulfate, sulfated oils such as the sulfuric ester of ricinoleic acid disodium salt, and sulfonated compounds such as alkyl sulfonates including sodium cetane sulfonate, amide sulfonates such as sodium N-methyl-N-oleyl laurate, sulfonated dibasic acid esters such as sodium dioctyl sulfosuccinate, alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate, alkyl naphthalene sulfonates such a sodium isopropyl naphthalene sulfonate, petroleum sulfonate such as aryl napthalene with alkyl substitutes. Examples of suitable cationic surfactants include amine salts such as octadecyl ammonium chloride, quarternary ammonium compounds such as benzalkonium chloride.
- Surfactants which are a mixture of sorbitan monostearate and
polysorbate 60 are preferred. - The emulsifier component may be present in any suitable stabilising amount. Preferably the emulsifier component may be in an amount where the ratio of emulsifier component to the occlusive agent, active pharmaceutical ingredient and cosolvent is about 1:5. The emulsifier component may be present in an amount of from approximately 1% to 15% by weight, preferably approximately 2.0% to 5.0% by weight, based on the total weight of the pharmaceutical mousse composition.
- The aqueous solvent may be present in an amount of from approximately 25% to 95% by weight, preferably approximately 70% to 85% by weight, based on the total weight of the pharmaceutical mousse composition.
- The composition further includes an organic cosolvent. The organic solvent may be an ester of a fatty acid for example a C12-C15 alkyl benzoate, a medium to long chain alcohol, an aromatic and/or alkyl pyrollidinone, an aromatic and/or alkyl, and/or cyclic ketone, an aromatic and/or alkyl, and/or cyclic ether, substituted and/or unsubstituted single or multiple ring aromatic, straight chain and/or branched chain and/or cyclic alkane or silicone. The organic cosolvent may be present in amounts of approximately 0.25% to 50% by weight, preferably 0.5 to 2% by weight, based on the total weight of the pharmaceutical mousse composition. Preferred organic cosolvents include C12-C15 alkyl benzoates (FINSOLV TN) and caprylic/capric triglyceride (CRODAMOL GTCC).
- The pharmaceutical mousse composition according to the present invention may also contain other non-essential ingredients. The composition may contain up to 10 weight percent of conventional pharmaceutical adjuvants. These adjuvants or additives include preservatives, stabilisers, antioxidants, pH adjusting agents, skin penetration enhancers, and viscosity modifying agents.
- The present invention will now be more fully described with reference to the accompanying figures and examples. It should be understood that the description following is illustrative only and should not be taken in any way as restrictive on the generality of the foregoing description.
-
FIG. 1 illustrates the effect of petrolatum content on in vitro epidermal penetration of clobetasol from topical mousse formulations 72 hours after application of 10 mg/cm2 of formulation. -
FIG. 2 illustrates the effect of petrolatum content on the rate of transepidermal water loss (TEWL) determined on the forearm of ahealthy volunteer -
FIG. 3 illustrates relative decreases in the rate of transepidermal water loss (TEWL) observed on the forearm of a healthy volunteer with increasing concentrations of petrolatum in topically applied formulations. -
FIG. 4 illustrates the effect of application of a 50% petrolatum mousse formulation on the relative rate of TEWL on the forearm of healthy volunteers (mean±SD, n=6). - A series of 7 pharmaceutical formulations were prepared in accordance with the present invention. The composition of each formulation is given in Table 1.
TABLE 1 Ingredient 1 2 3 4 5 6 7 Petrolatum 10% 10% 20% 30% 30% 40% 50% Clobetasol Propionate 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% Caprylic/Capric Triglyceride — — — — 10% — — Alkyl Benzoate 10% 10% 10% 10% — 10% 10% Cetearyl glucoside 2.5% — — — — — — Sorbitan Stearate — 1.63% 2.54% 3.44% 3.02% 4.35% 5.25 % Polysorbate 60 — 2.37% 3.46% 4.56% 4.98% 5.65% 6.75% Water 72.25% 70.95% 58.95% 46.95% 46.95% 34.95% 22.95% Preservatives 0.2% — — — — — — Propellent 5% 5% 5% 5% 5% 5% 5% - Alm
- The aim of the study was to:
-
- (1) determine the penetration of the steroid clobetasol into human epidermis following topical application of mousse formulations to which increasing concentrations of petrolatum had been included as a potential occlusive agent and penetration enhancer.
- (2) To assess clobetasol penetration following application to intact epidermis and that which had been stripped 3 times with tape to model the impaired stratum comeum barrier function seen in the dermatological conditions for which the drug is used clinically.
Method
- Preparation of epidermal membranes: Donated human female abdominal skin was separated by blunt dissection, to remove subcutaneous fat and extraneous tissue, and immersed in water at 60° C. for 2 minutes to allow separation of the epidermal-dermal junction. Epidermal membranes were lifted from the dermis by gently rolling from one end with the fingers and stored on filter paper, stratum comeum uppermost, at −20° C. until use.
- Diffusion Studies Epidermal membranes were mounted, stratum comeum uppermost and facing the donor chamber, on filter paper between the two halves of standard horizontal glass Franz-type diffusion cells (area approx. 1.3 cm2). The bottom half of the diffusion cells was filled with approximately 3.5 ml of receptor medium (either 20% ethanol in distilled water for intact epidermal membrane studies or
Baxter 20% Intralipid® solution for stripped skin studies) and continuously stirred with small magnetic fleas. Assembled cells were semi-submerged in a water bath maintained at 35±0.1° C. - Mousse formulations containing 0.05% clobetasol with the inclusion of 0, 30 or 50% petrolatum were gently applied to the donor chamber with a round-ended plastic rod which was wiped around the skin surface such that the skin was covered by a total dose of approximately 10 mg/cm2. The weight of formulation applied was verified from the difference in weight of the application rod and small weigh boat from which the formulation had been applied before and after dosing.
- Clobetasol was allowed to penetrate into the epidermis for 72 hrs. after which time the remaining formulation was removed from the skin surface by washing and a single tape strip was performed to ensure that minimal. ‘unpenetrated’ material remained on the surface of the epidermis. All washes and tape strips were retained for quantification of clobetasol concentration. The area of epidermis exposed to the formulation was then removed from the membrane using a stainless steel punch which was cleaned with methanol between samples to avoid any cross contamination of clobetasol. Epidermal, tape and wash samples were all assayed for clobetasol concentration by high performance liquid chromatography.
- Results
-
FIG. 1 shows the fraction of the applied amount of clobetasol that was found to have penetrated into the epidermal membranes during the study. It can be clearly seen that inclusion of petrolatum in the mousse formulations has increased the amount of clobetasol penetrating into the epidermis of both intact and stripped skin samples. The recovery of the applied amounts of clobetasol in the washes, tape strip and epidermis was greater than 75% in all cases. - Conclusion
- Increasing concentrations of petrolatum in topical mousse formulations containing 0.05% clobetasol was able to increase the in-vitro human epidermal penetration of the steroid in both intact and stripped skin models.
- Aim
- The aim of the study was to determine whether increasing the concentration of petrolatum in topical mousse formulations could effectively occlude the underlying skin and thereby lead to increased local hydration which in turn is known to improve the percutaneous penetration of suitable drugs.
- Method
- Relative degrees of occlusion of the skin in humans can be effectively quantified by following changes in the normal rate of transepidermal water loss (TEWL) caused by procedures such as formulation application. In the present study a commercially available single probe TEWL meter (Tewameter, Courage and Khazaka, Cologne, Germany) was used to determine the rate of TEWL (g/hr/m2) at a number of 2×2 cm numbered test squares marked on the medial side of the forearm of a healthy volunteer. Baseline readings of TEWL were taken in triplicate at each test site prior to the application of mousse formulation at a dose of 10 mg/cm2 containing 0, 10, 20, 30, 40 or 50% petrolatum. To ensure that the dose rate of 10 mg/cm2 was maintained for each formulation, approximately 40mg of each mousse was weighed out onto a 2 cm wide glass slide which was then used to wipe the mousse evenly across each one of the marked test squares before being reweighed to determine the total amount of mousse transferred onto the skin.
- At 30 and 120 minutes following mousse application determinations of TEWL were repeated at each of the test sites. Relative changes in TEWL were then calculated by dividing the rate of TEWL following application by that taken from the same marked square at t=0.
- Results
-
FIG. 2 shows the actual rate of TEWL (g/hr/m2) determined at each of the test sites prior to treatment and again at 30 and 120 minutes after mousse application. A decrease in the rate of TEWL was observed with Increasing concentrations of petrolatum in the mousse formulations at both 30 and 120 minutes following application.FIG. 2 clearly shows the relationship between the % of petrolatum content in each of the test mousses and the resultant relative change in the rate of TEWL determined at 30 and 120 minutes after formulation application. - Conclusion
- Increasing the concentration of petrolatum in topical mousse formulations was able to decrease the normal rate of TEWL on the forearm of a healthy volunteer. The decreases in the rate TEWL observed effectively demonstrate that increasing the concentration of petrolatum in the product leads to an increase in the relative occlusivity of the topical mousse formulations tested.
-
Part 2 - Aim
- The aim of the second part of this study was to assess the degree of occlusivity afforded by the 50% petrolatum mousse formulation in a number of healthy volunteers.
- Method
- The effect of a 10 mg/cm2 dose of 50% mousse formulation on the normal rate of TEWL was determined on the forearm of 6 volunteers in a manner identical to that described above. The relative changes observed in the rate of TEWL at 30 and 120 min after application were then compared to an untreated control site measured at the same time on the tested forearm of each volunteer.
- Results
-
FIG. 4 shows the relative rates of TEWL determined at the 2 test sites on the forearms of the volunteers. Significant decreases in TEWL (P<0.05, ANOVA and Students t-test) were observed at both the 30 and 120 min post-treatment tests following application of the 50% petrolatum mousse formulation. No significant difference was observed in the rate of TEWL between the control sites over the 120 min test period (P=0.19, ANOVA). - Conclusion
- Application of a mousse formulation containing 50% petrolatum at a dose of 10 mg/cm2 significantly occluded the skin as determined by decreases in the rate of TEWL observed on the forearms of 6 healthy volunteers.
- Finally, it is to be understood that various alterations, modifications and/or additions may be made without departing from the spirit of the present invention as outlined herein.
Claims (35)
1. A method for increasing skin permeability of an active agent, said method comprising:
applying a topical mousse composition comprising
(a) an occlusive agent;
(b) an aqueous solvent;
(c) an organic cosolvent; and
(d) an active agent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin to increase skin permeability of said active agent.
2. A method for reducing trans epidermal water loss with the topical application of an active agent, said method comprising:
applying a topical mousse composition comprising
(a) an occlusive agent;
(b) an aqueous solvent;
(c) an organic cosolvent; and
(d) an active agent, where after application of said composition, trans epidermal water loss is reduced.
3. A method for topical application of an active agent, said method comprising:
applying a topical mousse composition comprising
(a) an occlusive agent;
(b) an aqueous solvent;
(c) an organic cosolvent; and
(d) an active agent.
4. The method according to claims 1 or 2 or 3, wherein the occlusive agent comprises petrolatum.
5. The method according to claims 1 or 2 or 3, wherein the occlusive agent further comprises a mineral oil and a long chain acid.
6. The method according to claims 1 or 2 or 3, wherein the occlusive agent is selected from the group consisting of a mineral oil and grease, a long chain acid, an animal fat and grease, a vegetable fat and grease, and a water insoluble polymer.
7. The method according to claim 6 , wherein the occlusive agent is an animal fat or animal grease.
8. The method according to claims 1 or 2 or 3 wherein the occlusive agent is present in an amount of approximately 55% by weight or less, based on the total weight of the composition.
9. The method according to claim 8 , wherein the occlusive agent is present in an amount of approximately 10 to 50% by weight, based on the total weight of the composition.
10. The method according to claims 1 or 2 or 3, further comprising an effective amount of an emulsifier component.
11. The method according to claim 10 , wherein the emulsifier component is present in an amount of from approximately 1% to 15% by weight, based on the total weight of the composition.
12. The method according to claim 11 , wherein the emulsifier component is present in an amount of from approximately 2% to 5% by weight, based on the total weight of the composition.
13. The method according to claim 10 , wherein the emulsifier component is selected from the group consisting of a non-ionic surfactant, a cationic surfactant, an anionic surfactant, a fatty alcohol, a fatty acid, and fatty acid salts thereof.
14. The method according to claim 10 , wherein the emulsifier component comprises a mixture of a sorbitan ester and a polyoxyethylene fatty alcohol ether.
15. The method according to claim 10 , wherein the emulsifier component comprises a fatty alcohol, a fatty acid or a fatty acid salt.
16. The method according to claims 1 or 2 or 3, wherein the aqueous solvent is present in an amount of approximately 25 to 95% by weight, based on the total weight of the composition.
17. The method according to claims 1 or 2 or 3, wherein the organic cosolvent is present in an amount of approximately 0.25% by weight to 50% by weight, based on the total weight of the composition.
18. The method according to claim 17 , wherein the organic cosolvent is present in an amount of approximately 0.5% by weight to 2.0% by weight, based on the total weight of the composition.
19. The method according to claims 1 or 2 or 3, wherein the organic cosolvent comprises an ester of a fatty acid.
20. The method according to claims 1 or 2 or 3, wherein the organic cosolvent is selected from the group consisting of a medium to long chain alcohol, an aromatic and/or alkyl pyrollidinone, an aromatic and/or alkyl, and/or cyclic ketone, an aromatic and/or alkyl, and/or cyclic ether, substituted and/or unsubstituted single or multiple ring aromatic, straight chain and/or branched chain and/or cyclic alkane or silicone.
21. The method according to claims 1 or 2 or 3, further comprising an effective amount of an aerosol propellant.
22. The method according to claim 21 , wherein the aerosol propellant is a hydrocarbon and is present in an amount of approximately 2.5 to 20% by weight, based on the total weight of the composition.
23. The method according to claims 1 or 2 or 3 wherein said active agent is selected from the group consisting of an analgesic, an antifungal, an antibacterial, an anesthetic, an antiviral, an antipruritic, an antihistamine, a xanthine, a sex hormone, an anti-inflammatory, and a corticosteroid.
24. The method according to claim 23 , wherein said active agent is an anti-inflammatory.
25. The method according to claim 23 , wherein the active agent is insoluble in water.
26. The method according to claim 23 , wherein the active agent is insoluble in the occlusive agent.
27. The method according to claim 23 , wherein the active agent is insoluble in both water and the occlusive agent.
28. The method according to claim 23 , wherein the pharmaceutically active ingredient is present in an amount of from approximately 0.005% by weight to approximately 10% by weight, based on the total weight of the composition.
29. The method according to claim 23 , wherein the pharmaceutically active ingredient is present in an amount of from approximately 0.05% by weight to approximately 1% by weight, based on the total weight of the composition.
30. The method according to claim 23 , wherein said active agent is a corticosteroid.
31. The method according to claim 23 or 30 , wherein said active agent is more than one active agent.
32. The method according to claim 30 , wherein said corticosteroid is a member selected from the group consisting of betamethasone valerate and clobetasol propionate.
33. The method according to claim 23 , wherein said active agent is an antibacterial agent.
34. The method according to claim 33 , wherein said active agent is more than one active agent.
35. The method according to claims 1 or 2 or 3 wherein said mousse composition further comprises at least one member selected from the group consisting of a preservative, a stabilizer, an antioxidant, a pH adjusting agent, a skin penetration enhancer, and a viscosity modifying agent.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/303,298 US20060104912A1 (en) | 1998-09-11 | 2005-12-16 | Mousse composition |
US11/420,700 US8263580B2 (en) | 1998-09-11 | 2006-05-26 | Vitamin formulation |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP5831 | 1998-09-11 | ||
AUPP5831A AUPP583198A0 (en) | 1998-09-11 | 1998-09-11 | Mousse composition |
PCT/AU1999/000735 WO2000015193A1 (en) | 1998-09-11 | 1999-09-08 | Mousse composition |
US09/719,662 US6730288B1 (en) | 1998-09-11 | 1999-09-08 | Mousse composition |
US10/766,202 US7029659B2 (en) | 1998-09-11 | 2004-01-27 | Mousse composition |
US11/303,298 US20060104912A1 (en) | 1998-09-11 | 2005-12-16 | Mousse composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/766,202 Continuation US7029659B2 (en) | 1998-09-11 | 2004-01-27 | Mousse composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/420,700 Continuation-In-Part US8263580B2 (en) | 1998-09-11 | 2006-05-26 | Vitamin formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060104912A1 true US20060104912A1 (en) | 2006-05-18 |
Family
ID=3810055
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/719,662 Expired - Lifetime US6730288B1 (en) | 1998-09-11 | 1999-09-08 | Mousse composition |
US10/766,202 Expired - Lifetime US7029659B2 (en) | 1998-09-11 | 2004-01-27 | Mousse composition |
US11/303,298 Abandoned US20060104912A1 (en) | 1998-09-11 | 2005-12-16 | Mousse composition |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/719,662 Expired - Lifetime US6730288B1 (en) | 1998-09-11 | 1999-09-08 | Mousse composition |
US10/766,202 Expired - Lifetime US7029659B2 (en) | 1998-09-11 | 2004-01-27 | Mousse composition |
Country Status (13)
Country | Link |
---|---|
US (3) | US6730288B1 (en) |
EP (2) | EP1872776B1 (en) |
JP (1) | JP4603164B2 (en) |
AT (1) | ATE381315T1 (en) |
AU (2) | AUPP583198A0 (en) |
BR (1) | BR9913154A (en) |
CA (1) | CA2333869C (en) |
DE (1) | DE69937802T2 (en) |
DK (1) | DK1112062T3 (en) |
ES (2) | ES2299258T3 (en) |
NZ (1) | NZ508259A (en) |
PT (1) | PT1112062E (en) |
WO (1) | WO2000015193A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292080A1 (en) * | 1998-09-11 | 2006-12-28 | Connetics Australia Pty Ltd | Vitamin formulation |
US20110014135A1 (en) * | 2005-06-01 | 2011-01-20 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9504265D0 (en) | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
AUPO983897A0 (en) | 1997-10-17 | 1997-11-06 | Soltec Research Pty Ltd | Topical antifungal composition |
AUPP310798A0 (en) | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
FR2761600B1 (en) * | 1998-06-19 | 2000-03-31 | Oreal | FOAMING COMPOSITION FOR THE WASHING AND TREATMENT OF HAIR AND / OR SCALP BASED ON AN ACTIVE INGREDIENT, AN ANIONIC SURFACTANT, AN AMPHOTERIC SURFACTANT AND A PROPENETANT |
AUPP583198A0 (en) * | 1998-09-11 | 1998-10-01 | Soltec Research Pty Ltd | Mousse composition |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
JP2003012501A (en) * | 2001-06-27 | 2003-01-15 | Rohto Pharmaceut Co Ltd | Antipruritic aerosol preparation |
US20050129722A1 (en) * | 2002-03-13 | 2005-06-16 | Collagenex Pharmaceuticals, Inc. | Water-based delivery systems |
ES2411656T3 (en) * | 2002-03-13 | 2013-07-08 | Thomas SKÖLD | Water based management systems |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US20080031907A1 (en) * | 2002-10-25 | 2008-02-07 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) * | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
EP1556009B2 (en) | 2002-10-25 | 2021-07-21 | Foamix Pharmaceuticals Ltd. | Cosmetic and pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8119150B2 (en) * | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8900554B2 (en) * | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
EP1592420B1 (en) | 2003-01-24 | 2014-01-01 | Stiefel Research Australia Pty Ltd | Clindamycin phosphate foam |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
JP4377879B2 (en) * | 2003-05-13 | 2009-12-02 | 日清オイリオグループ株式会社 | Oil-in-water emulsified cosmetic |
US7186416B2 (en) | 2003-05-28 | 2007-03-06 | Stiefel Laboratories, Inc. | Foamable pharmaceutical compositions and methods for treating a disorder |
JP4615198B2 (en) * | 2003-07-25 | 2011-01-19 | 久光製薬株式会社 | Antifungal aerosol topical preparation |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
CA2536482C (en) * | 2003-08-25 | 2012-07-24 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8940321B2 (en) | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
WO2005055921A2 (en) * | 2003-12-12 | 2005-06-23 | Eran Eilat | Compositions for treatment of ear disorders and methods of use thereof |
EP1727522A2 (en) * | 2004-02-04 | 2006-12-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam with solid matter |
US8697712B2 (en) * | 2004-04-05 | 2014-04-15 | Laboratorios Liomont, S.A. De C.V. | Presentation of an antiviral pharmaceutical composition |
CA2610662A1 (en) * | 2005-05-09 | 2007-05-18 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
EP1879595B1 (en) | 2005-05-10 | 2014-09-24 | Dermipsor Ltd | Compositions and methods for treating hyperproliferative epidermal diseases |
US20060264344A1 (en) * | 2005-05-23 | 2006-11-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Mild foaming cleansing composition |
WO2007046102A2 (en) | 2005-10-19 | 2007-04-26 | Menni Menashe Zinger | Methods for the treatment of hyperhidrosis |
EP2206494B1 (en) | 2006-03-31 | 2015-12-02 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
EP2046121B1 (en) * | 2006-07-14 | 2012-08-22 | Stiefel Research Australia Pty Ltd | Fatty acid pharmaceutical foam |
US20080260655A1 (en) * | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
WO2009007785A2 (en) * | 2006-11-14 | 2009-01-15 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
AR066901A1 (en) * | 2007-05-18 | 2009-09-23 | Alcon Mfg Ltd | PHODFOLIPID COMPOSITIONS FOR THE CLOSURE OF CONTACT LENSES AND PRESERVATION OF PHARMACEUTICAL COMPOSITIONS |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
TW201010727A (en) * | 2008-09-03 | 2010-03-16 | Alcon Res Ltd | Pharmaceutical composition having relatively low ionic strength |
DK2400951T3 (en) | 2009-02-25 | 2018-12-03 | Mayne Pharma Llc | TOPICAL FOAM COMPOSITION |
FR2943914A1 (en) * | 2009-04-06 | 2010-10-08 | Fabre Pierre Dermo Cosmetique | MOISTURE BOTTLE COMPRISING A PHARMACEUTICAL COMPOSITION |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
EP2335675B1 (en) | 2009-12-10 | 2015-02-18 | Neubourg Skin Care GmbH & Co. KG | Emulsifier-free, polymer stabilised foam formulas |
CA2796575C (en) | 2010-04-13 | 2018-05-15 | Relmada Therapeutics, Inc. | Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use |
KR101619077B1 (en) | 2010-06-11 | 2016-05-10 | 레오 파마 에이/에스 | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid |
WO2013011501A1 (en) | 2011-07-20 | 2013-01-24 | Perrigo Israel Pharmaceuticals Ltd | Topical oily foam compositions |
US8911754B2 (en) | 2011-10-11 | 2014-12-16 | Fallien Cosmeceuticals, Ltd. | Foamable sunscreen formulation |
WO2013065051A1 (en) | 2011-11-01 | 2013-05-10 | Naveh Pharma (1996) Ltd. | Formulation and device for treating ceruminosis |
CA2896429A1 (en) | 2012-12-26 | 2014-07-03 | Otic Pharma Ltd. | Foamable otic pharmaceutical compositions |
WO2015123238A1 (en) * | 2014-02-14 | 2015-08-20 | Mission Pharmacal Company | Stabilized, sprayable emulsion containing active agent particles |
CA2936409C (en) | 2014-02-14 | 2023-03-14 | Mission Pharmacal Company | Spray delivery device |
ES2894679T3 (en) | 2014-02-14 | 2022-02-15 | Mission Pharma Co | Sprayable composition containing zinc oxide and a fluoro-olefin propellant |
BR112016022293A2 (en) | 2014-03-28 | 2017-08-15 | Galderma Res & Dev | COMPOSITION CONTAINING BENZOYL PEROXIDE, COSMETIC USE OF A COMPOSITION, DRUG INTENDED FOR TOPICAL APPLICATION ON THE SKIN, KIT AND PROCESS FOR PREPARING A SELF-FOAMING COMPOSITION |
US9265727B1 (en) | 2015-01-14 | 2016-02-23 | Delcor Asset Corporation | Spray foam corticosteroid product |
CA2974196C (en) | 2015-01-20 | 2023-12-12 | TetraDerm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
US10716740B2 (en) | 2015-03-24 | 2020-07-21 | The Procter & Gamble Company | Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin |
FR3041535B1 (en) | 2015-09-29 | 2019-01-25 | Galderma Research & Development | NON-RINSE CHEMICAL FOAM CONTAINING TRIFAROTENE AND USE THEREOF IN THE TREATMENT OF ICHTYOSE |
FR3041536B1 (en) | 2015-09-29 | 2018-11-30 | Galderma Research & Development | NON-RINSEED CHEMICAL FOAM CONTAINING TRIFAROTENE AND USE THEREOF IN THE TREATMENT OF ACNE |
FR3041538B1 (en) * | 2015-09-29 | 2018-11-30 | Galderma Research & Development | NON-RINSE CHEMICAL FOAM CONTAINING CLOBETASOL PROPIONATE AND USE THEREOF IN THE TREATMENT OF PSORIASIS |
FR3041541B1 (en) | 2015-09-29 | 2018-11-30 | Galderma Research & Development | NON-RINSE CHEMICAL FOAM COMPRISING IVERMECTIN |
FR3041537B1 (en) | 2015-09-29 | 2018-11-30 | Galderma Research & Development | BRIMONIDINE CONTAINING CHEMICAL FOAM WITHOUT RINSE AND USE THEREOF FOR TREATING ROSACEA. |
FR3041539B1 (en) * | 2015-09-29 | 2018-10-26 | Galderma Research & Development | SELF-FOAMING CLEANING COMPOSITION CONTAINING CLOBETASOL PROPIONATE AND USE THEREOF IN THE TREATMENT OF PSORIASIS |
MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
US11617727B2 (en) | 2019-04-30 | 2023-04-04 | Bayer Healthcare Llc | Topical analgesic gel compositions |
Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3330730A (en) * | 1962-08-03 | 1967-07-11 | Colgate Palmolive Co | Pressurized emulsion quick breaking foam compositions |
US3829563A (en) * | 1972-11-30 | 1974-08-13 | Hoffmann La Roche | Emollient cleansing compositions |
US4098882A (en) * | 1974-09-26 | 1978-07-04 | L'oreal | Anti-solar composition |
US4185100A (en) * | 1976-05-13 | 1980-01-22 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
US4267173A (en) * | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
US4293542A (en) * | 1976-05-03 | 1981-10-06 | L'oreal | Cosmetic composition for imparting to human skin a coloration resembling a natural tan |
US4305936A (en) * | 1980-10-09 | 1981-12-15 | Dermik Laboratories | Topical corticosteroid formulations |
US4317817A (en) * | 1979-08-27 | 1982-03-02 | Richardson-Merrell Inc. | Novel steroid 5α-reductase inhibitors |
US4607028A (en) * | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
US4618344A (en) * | 1982-06-01 | 1986-10-21 | The Procter & Gamble Company | Depilatory compositions |
US4631064A (en) * | 1982-06-01 | 1986-12-23 | The Proctor & Gamble Company | Depilatory compositions |
US4847068A (en) * | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
US4871723A (en) * | 1984-10-08 | 1989-10-03 | Teijin, Limited | Method for treating psoriasis by externally administering to a patient a pharmaceutical composition containing active-type vitamin D |
US4981679A (en) * | 1983-06-08 | 1991-01-01 | Briggs Joseph H | Method and composition for the treatment of burns |
US4981677A (en) * | 1987-09-23 | 1991-01-01 | L'oreal | Petrolatum-containing aerosol foam concentrate |
US4992478A (en) * | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US5037655A (en) * | 1990-04-18 | 1991-08-06 | Giovanoni Richard L | Method of stabilizing tretinoin |
US5143717A (en) * | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
US5167950A (en) * | 1991-03-28 | 1992-12-01 | S. C. Johnson & Son | High alcohol content aerosol antimicrobial mousse |
US5252331A (en) * | 1992-03-05 | 1993-10-12 | Lorenzo Freeman | Less irritating shaving material |
US5658559A (en) * | 1992-12-16 | 1997-08-19 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
US5733558A (en) * | 1995-04-20 | 1998-03-31 | L'oreal | Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same |
US5834511A (en) * | 1994-03-24 | 1998-11-10 | Ciba Specialty Chemicals Corporation | DL- DI- or tri-hydroxyphenylglycine alkyl esters for the treatment of inflammatory and allergic conditions |
US5833960A (en) * | 1996-08-02 | 1998-11-10 | Beiersdorf Ag | Foaming light protection preparations containing water-soluble light protection filters and surface-active substances |
US5902805A (en) * | 1996-04-22 | 1999-05-11 | L'oreal | Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same |
US5976555A (en) * | 1994-09-07 | 1999-11-02 | Johnson & Johnson Consumer Products, Inc. | Topical oil-in-water emulsions containing retinoids |
US6075056A (en) * | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6126920A (en) * | 1995-03-03 | 2000-10-03 | Medeva Europe Plc | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
US6228887B1 (en) * | 1997-05-09 | 2001-05-08 | Douglas E. Kligman | Method of treating skin disorders with high-strength retinoids |
US6423323B2 (en) * | 1997-08-18 | 2002-07-23 | Stephanie Neubourg | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
US6730288B1 (en) * | 1998-09-11 | 2004-05-04 | Connetics Australia Pty Ltd | Mousse composition |
US20050281755A1 (en) * | 2004-06-17 | 2005-12-22 | Galderma S.A. | Topical foam/mousse compositions for treating psoriasis |
US20070269379A1 (en) * | 2003-07-23 | 2007-11-22 | Samir Mitragotri | Penetration Enhancer Combinations for Transdermal Delivery |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE52185T1 (en) * | 1985-03-01 | 1990-05-15 | Procter & Gamble | MILD CLEANING FOAM. |
DE309353T1 (en) * | 1987-09-23 | 1991-02-07 | L'oreal, Paris, Fr | SKIN TREATMENT AGENT AS AEROSOL FOAM CONTAINING VASILINE. |
JP2741105B2 (en) * | 1989-07-28 | 1998-04-15 | 久光製薬株式会社 | Foam aerosol formulation |
US5420106A (en) * | 1994-03-22 | 1995-05-30 | Bristol-Myers Squibb Company | Method and composition having enhanced alpha-hydroxy acid skin permeation and retention |
GB2327344A (en) * | 1997-07-18 | 1999-01-27 | Ninh Thuy On | Pharmaceutical compositions containing phenytoin and either an azole anti-fungal/anti-bacterial agent and/or a silver salt for topical application |
US5965500A (en) | 1997-07-24 | 1999-10-12 | Levers Brothers Company, Division Of Conopco, Inc. | Stable liquid composition comprising high levels of emollients |
-
1998
- 1998-09-11 AU AUPP5831A patent/AUPP583198A0/en not_active Abandoned
-
1999
- 1999-09-08 PT PT99947098T patent/PT1112062E/en unknown
- 1999-09-08 AT AT99947098T patent/ATE381315T1/en active
- 1999-09-08 CA CA002333869A patent/CA2333869C/en not_active Expired - Lifetime
- 1999-09-08 DK DK99947098T patent/DK1112062T3/en active
- 1999-09-08 ES ES99947098T patent/ES2299258T3/en not_active Expired - Lifetime
- 1999-09-08 JP JP2000569777A patent/JP4603164B2/en not_active Expired - Lifetime
- 1999-09-08 ES ES07118237T patent/ES2431330T3/en not_active Expired - Lifetime
- 1999-09-08 BR BR9913154-4A patent/BR9913154A/en not_active Application Discontinuation
- 1999-09-08 EP EP07118237.2A patent/EP1872776B1/en not_active Expired - Lifetime
- 1999-09-08 AU AU60692/99A patent/AU760153B2/en not_active Expired
- 1999-09-08 DE DE69937802T patent/DE69937802T2/en not_active Expired - Lifetime
- 1999-09-08 US US09/719,662 patent/US6730288B1/en not_active Expired - Lifetime
- 1999-09-08 NZ NZ508259A patent/NZ508259A/en not_active IP Right Cessation
- 1999-09-08 WO PCT/AU1999/000735 patent/WO2000015193A1/en active IP Right Grant
- 1999-09-08 EP EP99947098A patent/EP1112062B1/en not_active Expired - Lifetime
-
2004
- 2004-01-27 US US10/766,202 patent/US7029659B2/en not_active Expired - Lifetime
-
2005
- 2005-12-16 US US11/303,298 patent/US20060104912A1/en not_active Abandoned
Patent Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3330730A (en) * | 1962-08-03 | 1967-07-11 | Colgate Palmolive Co | Pressurized emulsion quick breaking foam compositions |
US3829563A (en) * | 1972-11-30 | 1974-08-13 | Hoffmann La Roche | Emollient cleansing compositions |
US4098882A (en) * | 1974-09-26 | 1978-07-04 | L'oreal | Anti-solar composition |
US4293542A (en) * | 1976-05-03 | 1981-10-06 | L'oreal | Cosmetic composition for imparting to human skin a coloration resembling a natural tan |
US4185100A (en) * | 1976-05-13 | 1980-01-22 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
US4317817A (en) * | 1979-08-27 | 1982-03-02 | Richardson-Merrell Inc. | Novel steroid 5α-reductase inhibitors |
US4267173A (en) * | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
US4305936A (en) * | 1980-10-09 | 1981-12-15 | Dermik Laboratories | Topical corticosteroid formulations |
US4618344A (en) * | 1982-06-01 | 1986-10-21 | The Procter & Gamble Company | Depilatory compositions |
US4631064A (en) * | 1982-06-01 | 1986-12-23 | The Proctor & Gamble Company | Depilatory compositions |
US4981679A (en) * | 1983-06-08 | 1991-01-01 | Briggs Joseph H | Method and composition for the treatment of burns |
US4607028A (en) * | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
US4871723A (en) * | 1984-10-08 | 1989-10-03 | Teijin, Limited | Method for treating psoriasis by externally administering to a patient a pharmaceutical composition containing active-type vitamin D |
US4847068A (en) * | 1987-08-06 | 1989-07-11 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions |
US4981677A (en) * | 1987-09-23 | 1991-01-01 | L'oreal | Petrolatum-containing aerosol foam concentrate |
US5143717A (en) * | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
US4992478A (en) * | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US5037655A (en) * | 1990-04-18 | 1991-08-06 | Giovanoni Richard L | Method of stabilizing tretinoin |
US5167950A (en) * | 1991-03-28 | 1992-12-01 | S. C. Johnson & Son | High alcohol content aerosol antimicrobial mousse |
US5252331A (en) * | 1992-03-05 | 1993-10-12 | Lorenzo Freeman | Less irritating shaving material |
US5658559A (en) * | 1992-12-16 | 1997-08-19 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
US5834511A (en) * | 1994-03-24 | 1998-11-10 | Ciba Specialty Chemicals Corporation | DL- DI- or tri-hydroxyphenylglycine alkyl esters for the treatment of inflammatory and allergic conditions |
US5976555A (en) * | 1994-09-07 | 1999-11-02 | Johnson & Johnson Consumer Products, Inc. | Topical oil-in-water emulsions containing retinoids |
US6126920A (en) * | 1995-03-03 | 2000-10-03 | Medeva Europe Plc | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
US5733558A (en) * | 1995-04-20 | 1998-03-31 | L'oreal | Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same |
US5902805A (en) * | 1996-04-22 | 1999-05-11 | L'oreal | Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same |
US5833960A (en) * | 1996-08-02 | 1998-11-10 | Beiersdorf Ag | Foaming light protection preparations containing water-soluble light protection filters and surface-active substances |
US6228887B1 (en) * | 1997-05-09 | 2001-05-08 | Douglas E. Kligman | Method of treating skin disorders with high-strength retinoids |
US6423323B2 (en) * | 1997-08-18 | 2002-07-23 | Stephanie Neubourg | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
US6075056A (en) * | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6730288B1 (en) * | 1998-09-11 | 2004-05-04 | Connetics Australia Pty Ltd | Mousse composition |
US7029659B2 (en) * | 1998-09-11 | 2006-04-18 | Connetics Australia Pty Ltd. | Mousse composition |
US20070269379A1 (en) * | 2003-07-23 | 2007-11-22 | Samir Mitragotri | Penetration Enhancer Combinations for Transdermal Delivery |
US20050281755A1 (en) * | 2004-06-17 | 2005-12-22 | Galderma S.A. | Topical foam/mousse compositions for treating psoriasis |
Non-Patent Citations (1)
Title |
---|
Sharif (Sharif, F., et al., Arch Dis Child (2001) 85, pgs. 121-124) * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292080A1 (en) * | 1998-09-11 | 2006-12-28 | Connetics Australia Pty Ltd | Vitamin formulation |
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US20110014135A1 (en) * | 2005-06-01 | 2011-01-20 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US8298515B2 (en) | 2005-06-01 | 2012-10-30 | Stiefel Research Australia Pty Ltd. | Vitamin formulation |
US8629128B2 (en) | 2005-06-01 | 2014-01-14 | Stiefel West Coast, Llc | Vitamin formulation |
Also Published As
Publication number | Publication date |
---|---|
CA2333869C (en) | 2009-01-06 |
DE69937802D1 (en) | 2008-01-31 |
WO2000015193A1 (en) | 2000-03-23 |
US7029659B2 (en) | 2006-04-18 |
AU760153B2 (en) | 2003-05-08 |
PT1112062E (en) | 2008-03-24 |
EP1112062A1 (en) | 2001-07-04 |
EP1872776A3 (en) | 2008-07-23 |
DK1112062T3 (en) | 2008-04-28 |
AU6069299A (en) | 2000-04-03 |
US20040184992A1 (en) | 2004-09-23 |
ATE381315T1 (en) | 2008-01-15 |
NZ508259A (en) | 2003-11-28 |
EP1872776B1 (en) | 2013-07-24 |
AUPP583198A0 (en) | 1998-10-01 |
JP2002524490A (en) | 2002-08-06 |
ES2299258T3 (en) | 2008-05-16 |
EP1112062B1 (en) | 2007-12-19 |
DE69937802T2 (en) | 2008-12-04 |
ES2431330T3 (en) | 2013-11-26 |
BR9913154A (en) | 2001-05-15 |
US6730288B1 (en) | 2004-05-04 |
EP1112062A4 (en) | 2005-06-08 |
EP1872776A2 (en) | 2008-01-02 |
CA2333869A1 (en) | 2000-03-23 |
JP4603164B2 (en) | 2010-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6730288B1 (en) | Mousse composition | |
AU2006253913B2 (en) | Vitamin formulation | |
US8263580B2 (en) | Vitamin formulation | |
US10588858B2 (en) | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof | |
US4661524A (en) | Topical treatment and composition | |
KR101930246B1 (en) | Topical corticosteroid compositions | |
US20070224143A1 (en) | Cosmetic and pharmaceutical foam carrier | |
EP0303713A1 (en) | Percutaneous absorption promoter and dermatologic preparation for external use | |
US8664205B2 (en) | Oil-in-water emulsion lotion containing 22-oxa-1α, 25-dihydroxyvitamin D3 and method of treatment of skin disorder using the same | |
MXPA00012204A (en) | Mousse composition | |
EP4247349A1 (en) | Gel, ointment, and foam formulations of tapinarof and methods of use | |
NZ223913A (en) | Percutaneous absorption promoting agent containing an anionic surfactant and a nitrogen-containing surfactant other than an anionic surfactant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: STIEFEL WEST COAST, LLC, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STIEFEL RESEARCH AUSTRALIA PTY LTD;REEL/FRAME:030511/0963 Effective date: 20130530 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |